AT-1412 is under clinical development by Kling Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AT-1412’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AT-1412 overview

KBA-1412 is under development for the treatment of solid tumors, melanoma. It acts by targeting cells expressing CD9 epitope. It is a fully human monoclonal antibody developed based on AIMSelect and AIMProve platforms. It was also under development for colon cancer, pancreatic cancer , melanoma, solid tumors B-cell acute lymphoblastic leukemia, gastric, breast, esophageal cancer.and multiple myeloma. It is administered through intravenous route.

Kling Biotherapeutics overview

Kling Biotherapeutics (Kling Bio) is a biotherapeutics discovery and development company focusing on novel antibody based therapeutics. Kling Bio is headquartered in Amsterdam, the Netherlands.

For a complete picture of AT-1412’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.